Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia.
Res Pract Thromb Haemost
; 7(4): 100183, 2023 May.
Article
en En
| MEDLINE
| ID: mdl-37538495
ABSTRACT
Background:
Glanzmann thrombasthenia (GT) is a rare congenital platelet function disorder associated with a severe bleeding diathesis. Thrombotic manifestations remain a rare condition. We report here the first case of recurrent venous thromboembolism (VTE) successfully treated with apixaban in a patient with GT. Our patient's morbid obesity was an additional challenge. Key Clinical Question The Key Clinical Question was to determine if direct oral anticoagulants are suitable for patients with both obesity and GT. ClinicalApproach:
In our patient, the first episode of VTE occurred after the use of a low dose of activated recombinant factor VII for a minor procedure, whereas the second was unprovoked. Administration of rivaroxaban very quickly led to the appearance of bleeding symptoms and subsequently led to poor compliance and extension of deep vein thrombosis. The patient was switched to apixaban, with very good efficacy and safety over the cumulative 18 months of use.Conclusion:
The last updated guidelines now recommend the use of rivaroxaban and apixaban for management of VTE in patients with obesity. Regarding patients with GT, there is still insufficient data on the use of direct oral anticoagulants. Management of thrombotic manifestations in these patients remains a rare and complex condition and could be improved by the creation of a specific international registry.
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Guideline
/
Prognostic_studies
Idioma:
En
Revista:
Res Pract Thromb Haemost
Año:
2023
Tipo del documento:
Article
País de afiliación:
Francia